Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 3/2017

01-06-2017 | ORIGINAL ARTICLE

Primary Care Physician Perspectives on Barriers to Statin Treatment

Authors: Rikki M. Tanner, Monika M. Safford, Keri L. Monda, Benjamin Taylor, Ronan O’Beirne, Melanie Morris, Lisandro D. Colantonio, Ricardo Dent, Paul Muntner, Robert S. Rosenson

Published in: Cardiovascular Drugs and Therapy | Issue 3/2017

Login to get access

Abstract

Purpose

Discontinuation of statin therapy represents a major challenge for effective cardiovascular disease prevention. It is unclear how often primary care physicians (PCPs) re-initiate statins and what barriers they encounter. We aimed to identify PCP perspectives on factors influencing statin re-initiation.

Methods

We conducted six nominal group discussions with 23 PCPs from the Deep South Continuing Medical Education network. PCPs answered questions about statin side effects, reasons their patients reported for discontinuing statins, how they respond when discontinuation is reported, and barriers they encounter in getting their patients to re-initiate statin therapy. Each group generated a list of responses in round-robin fashion. Then, each PCP independently ranked their top three responses to each question. For each PCP, the most important reason was given a weight of 3 votes, and the second and third most important reasons were given weights of 2 and 1, respectively. We categorized the individual responses into themes and determined the relative importance of each theme using a “percent of available votes” metric.

Results

PCPs reported that side effects, especially muscle/joint-related symptoms, were the most common reason patients reported for statin discontinuation (47% of available votes). PCPs reported statin re-challenge as their most common response when a patient discontinues statin use (31% of available votes). Patients’ fear of side effects was ranked as the biggest challenge PCPs encounter in getting their patients to re-initiate statin therapy (70% of available votes).

Conclusion

PCPs face challenges getting their patients to re-initiate statins, particularly after a patient reports side effects.
Appendix
Available only for authorised users
Literature
1.
go back to reference Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
2.
go back to reference Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.CrossRefPubMed Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.CrossRefPubMed
3.
go back to reference Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.CrossRefPubMed Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.CrossRefPubMed
4.
5.
go back to reference Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166(3):597–603.CrossRefPubMedPubMedCentral Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166(3):597–603.CrossRefPubMedPubMedCentral
6.
go back to reference Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, Hickner J. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. JABFM. 2006;19(1):46–53.CrossRefPubMed Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, Hickner J. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. JABFM. 2006;19(1):46–53.CrossRefPubMed
7.
go back to reference Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating “clinical inertia” from appropriate care. J Gen Int Med. 2007;22(12):1648–55.CrossRef Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating “clinical inertia” from appropriate care. J Gen Int Med. 2007;22(12):1648–55.CrossRef
8.
go back to reference Shewchuk R, O'Connor SJ. Using cognitive concept mapping to understand what health care means to the elderly: an illustrative approach for planning and marketing. Health Mark Q. 2002;20(2):69–88.CrossRefPubMed Shewchuk R, O'Connor SJ. Using cognitive concept mapping to understand what health care means to the elderly: an illustrative approach for planning and marketing. Health Mark Q. 2002;20(2):69–88.CrossRefPubMed
9.
go back to reference Levine DA, Saag KG, Casebeer LL, Colon-Emeric C, Lyles KW, Shewchuk RM. Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention. J Am Med Dir Assoc. 2006;7(7):420–5.CrossRefPubMedPubMedCentral Levine DA, Saag KG, Casebeer LL, Colon-Emeric C, Lyles KW, Shewchuk RM. Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention. J Am Med Dir Assoc. 2006;7(7):420–5.CrossRefPubMedPubMedCentral
10.
11.
go back to reference Hickling JA, Nazareth I, Rogers S. The barriers to effective management of heart failure in general practice. Brit J Gen Pract. 2001;51(469):615–8. Hickling JA, Nazareth I, Rogers S. The barriers to effective management of heart failure in general practice. Brit J Gen Pract. 2001;51(469):615–8.
12.
go back to reference Delbecq AL, Van de Ven AH. A group process model for problem identification and program planning. J Appl Behav Sci. 1971;7(4) Delbecq AL, Van de Ven AH. A group process model for problem identification and program planning. J Appl Behav Sci. 1971;7(4)
13.
go back to reference Van Breda A. Steps to analysing multiple-group NGT data. Soc Work Pract Res. 2005;17(1):1–14. Van Breda A. Steps to analysing multiple-group NGT data. Soc Work Pract Res. 2005;17(1):1–14.
14.
go back to reference Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;76(9):54C–9C.CrossRefPubMed Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;76(9):54C–9C.CrossRefPubMed
15.
go back to reference Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010;13(3):428–37.CrossRefPubMed Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010;13(3):428–37.CrossRefPubMed
16.
go back to reference Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmaco Economics. 2008;26(4):329–39.CrossRef Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmaco Economics. 2008;26(4):329–39.CrossRef
17.
go back to reference Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83.CrossRefPubMed Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83.CrossRefPubMed
18.
go back to reference Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.CrossRefPubMed Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.CrossRefPubMed
19.
go back to reference Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association’s Muscle Safety Expert Panel: an assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71.CrossRefPubMed Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association’s Muscle Safety Expert Panel: an assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71.CrossRefPubMed
20.
go back to reference Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6–15.CrossRefPubMed Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6–15.CrossRefPubMed
21.
go back to reference Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90.CrossRefPubMed Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90.CrossRefPubMed
22.
go back to reference Evans WJ, Cannon JG. The metabolic effects of exercise-induced muscle damage. Exerc Sport Sci Rev. 1991;19:99–125.CrossRefPubMed Evans WJ, Cannon JG. The metabolic effects of exercise-induced muscle damage. Exerc Sport Sci Rev. 1991;19:99–125.CrossRefPubMed
23.
go back to reference Rojas-Fernandez C, Hudani Z, Bittner V. Statins and cognitive side effects: what cardiologists need to know. Endocrinol Metab Clin N Am. 2016;45(1):101–16.CrossRef Rojas-Fernandez C, Hudani Z, Bittner V. Statins and cognitive side effects: what cardiologists need to know. Endocrinol Metab Clin N Am. 2016;45(1):101–16.CrossRef
24.
go back to reference Samaras K, Brodaty H, Sachdev PS. Does statin use cause memory decline in the elderly? Trends Cardiovasc Med. 2016;26(6):550–65.CrossRefPubMed Samaras K, Brodaty H, Sachdev PS. Does statin use cause memory decline in the elderly? Trends Cardiovasc Med. 2016;26(6):550–65.CrossRefPubMed
25.
go back to reference de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24(5):584–91.CrossRefPubMed de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24(5):584–91.CrossRefPubMed
26.
go back to reference Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349–56.CrossRefPubMedPubMedCentral Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349–56.CrossRefPubMedPubMedCentral
27.
go back to reference Boehme AK, Davies SL, Moneyham L, Shrestha S, Schumacher J, Kempf MC. A qualitative study on factors impacting HIV care adherence among postpartum HIV-infected women in the rural southeastern USA. AIDS Care. 2014;26(5):574–81.CrossRefPubMed Boehme AK, Davies SL, Moneyham L, Shrestha S, Schumacher J, Kempf MC. A qualitative study on factors impacting HIV care adherence among postpartum HIV-infected women in the rural southeastern USA. AIDS Care. 2014;26(5):574–81.CrossRefPubMed
28.
go back to reference Becker WC, Dorflinger L, Edmond SN, Islam L, Heapy AA, Fraenkel L. Barriers and facilitators to use of non-pharmacological treatments in chronic pain. BMC Fam Pract. 2017;18(1):41.CrossRefPubMedPubMedCentral Becker WC, Dorflinger L, Edmond SN, Islam L, Heapy AA, Fraenkel L. Barriers and facilitators to use of non-pharmacological treatments in chronic pain. BMC Fam Pract. 2017;18(1):41.CrossRefPubMedPubMedCentral
Metadata
Title
Primary Care Physician Perspectives on Barriers to Statin Treatment
Authors
Rikki M. Tanner
Monika M. Safford
Keri L. Monda
Benjamin Taylor
Ronan O’Beirne
Melanie Morris
Lisandro D. Colantonio
Ricardo Dent
Paul Muntner
Robert S. Rosenson
Publication date
01-06-2017
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 3/2017
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-017-6738-x

Other articles of this Issue 3/2017

Cardiovascular Drugs and Therapy 3/2017 Go to the issue